Internal link ProQR to Participate in the Kempen Life Sciences Conference avril 19, 2022 at 08:30 PM UTC
Internal link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy avril 13, 2022 at 11:00 AM UTC
Internal link ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit avril 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit mars 23, 2022 at 08:30 PM UTC
Internal link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board mars 07, 2022 at 12:00 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results février 24, 2022 at 12:00 PM UTC
Internal link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 février 11, 2022 at 12:00 PM UTC
Internal link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen janvier 04, 2022 at 12:00 PM UTC